ANZCTR - Registration

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers

Trial registered on ANZCTR

Registration number

ACTRN12618000818235

Ethics application status

Approved

Date submitted

9/05/2018

Date registered

11/05/2018

Date last updated

8/08/2019

Date data sharing statement initially provided

8/08/2019

Type of registration

Prospectively registered

Titles & IDs

Public title

Effect of Warm Humidified Insufflation on Lens Fogging during Laparoscopic Cholecystectomy. A Single centre, superiority, blinded randomised controlled trial.

Scientific title

Effect of Warm Humidified Insufflation on Lens Fogging during Laparoscopic Cholecystectomy. A Single centre, superiority, blinded randomised controlled trial.

Secondary ID [1]

None

Universal Trial Number (UTN)

U1111-1203-2641

Trial acronym

Linked study record

Health condition

Health condition(s) or problem(s) studied:

Cholecystitis

Condition category

Condition code

Surgery

Surgical techniques

Oral and Gastrointestinal

Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure

Study type

Interventional

Description of intervention(s) / exposure

Eligible patients undergoing elective laparoscopic cholecystectomy at Auckland District Health Board will be approached to take part in the study. If the patient consents they will be randomised to either receive warmed and humidified CO2 insufflation using the Humigard device or standard CO2 insufflation during the procedure.

Intervention arm – Patients will receive humidified insufflation. This will be given by commercially available gas insufflation device. Connected to an insufflator, Humigard warms and humidifies the CO2 to 37oC and 100% relative humidity.

The images taken by the laparoscopic camera will be assessed during the procedure and the number of fogging events will be recorded by a research nurse. The images will be recorded and after the procedure they will be saved onto an external hard drive. Three experienced surgeons who are blinded to the treatment allocation will score the images and assess any fogging events.

There is no follow up for this study.

Intervention code [1]

Treatment: Surgery

Intervention code [2]

Treatment: Devices

Comparator / control treatment

Control arm – Patients will receive the same treatment for their cholecystitis and the camera will not be set up to receive Humigard.

The images taken by the laparoscope will be assessed during the procedure and the number of fogging events will be recorded by a research nurse. The images will be recorded and after the procedure they will be saved onto an external hard drive. Three experienced surgeons who are blinded to the treatment allocation will score the images and assess any fogging events.

A sub-set of de-identified, pooled video data will be shared with the engineering department of the sponsor, Fisher & Paykel Healthcare, to enable creation of an algorithm that is needed to analyse all caputured videos at completion of the study.

There is no follow up for this study.

Control group

Active

Outcomes

Primary outcome [1]

Number of fogging events recorded onto the case report form by a research nurse at the time of surgery.

Timepoint [1]

Throughout the surgical procedure by a research nurse and retrospectively based on review of laparoscopic recordings by a consultant.

Primary outcome [2]

Duration of fogging measured by a research nurse using a stopwatch.

Timepoint [2]

Throughout the surgical procedure by a research nurse and retrospectively based on review of laparoscopic recordings by a consultant.

Secondary outcome [1]

The combined subjective effort fogging had on the procedure as reported by the operating surgeon, assistant surgeon and scrub nurse. This will be measured using a Likert-like scale.

Timepoint [1]

Within one hour of completion of surgery.

Eligibility

Key inclusion criteria

1. Scheduled to undergo laparoscopic cholecystectomy
2. Able to give informed consent
3. Male or female 18 years of age or older.

Minimum age

18 Years

Maximum age

No limit

Sex

Both males and females

Can healthy volunteers participate?

Key exclusion criteria

1. Participant is pregnant

Study design

Purpose of the study

Treatment

Allocation to intervention

Randomised controlled trial

Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)

Patients are randomised using random numbers obtained by a computer-based random number generator. Concealment will be achieved by the use of opaque envelopes opened at surgery by a third party.

Methods used to generate the sequence in which subjects will be randomised (sequence generation)

Simple randomisation using a randomisation table created by computer software.

Masking / blinding

Blinded (masking used)

Who is / are masked / blinded?

The people receiving the treatment/s

The people analysing the results/data

Intervention assignment

Parallel

Other design features

Phase

Not Applicable

Type of endpoint/s

Efficacy

Statistical methods / analysis

Sample size calculation - To calculate the number of patients to be include in the trial the standard power parameter of 0.8 and a test level of 0.05 will be used. A recent study scored lens fogging using a scientific model which evaluated fogging on a scales from 1 to 4 and measured differences with a SD of 1. To account for possible increased variation in patients we increased the SD to 1.5, Thus, we used the SD value of 1.5, and a mean separation of one on the ordinal scale to separate the groups for substantive significance and to estimate a samples size. This generated a required sample size of 37 per arm, totaling 74 patients. Allowing for a drop out rate of 10% per group the numbers should be expanded to 61 in each arm or 122 in total.

Statistical analyses - Statistical difference between the two groups will be sought using independent sample t-tests for mean difference and Pearson’s chi-square tests for proportional differences. Odds ratios for effect size to be calculated along with confidence intervals. An alpha level of 0.05 to be used for all statistical tests. Analyses of effect of surgeon to be compared using independent sample t-tests and Cohen’s effect size. For demographic variables, an alpha test level of 0.05 under standard assumptions. Multivariable logistic regression for factors such as surgeon experience, operating centre etc. Kappa tests for reviewer agreement.

Recruitment

Recruitment status

Recruiting

Date of first participant enrolment

Anticipated

18/06/2018

Actual

8/06/2018

Date of last participant enrolment

Anticipated

Actual

Date of last data collection

Anticipated

Actual

Sample size

Target

122

Accrual to date

Final

Recruitment outside Australia

Country [1]

New Zealand

State/province [1]

Auckland

Funding & Sponsors

Funding source category [1]

Commercial sector/Industry

Name [1]

Fisher and Paykel Healthcare

Address [1]

15 Maurice Paykel Place
East Tamaki
Auckland
2013

Country [1]

New Zealand

Primary sponsor type

Commercial sector/Industry

Name

Fisher and Paykel Healthcare

Address

15 Maurice Paykel Place
East Tamaki
Auckland
2013

Country

New Zealand

Secondary sponsor category [1]

None

Name [1]

Address [1]

Country [1]

Ethics approval

Ethics application status

Approved

Ethics committee name [1]

Southern Health and Disability Ethics Committee

Ethics committee address [1]

Ministry of Health
133 Molesworth Street
PO Box 5013
Wellington
6011

Ethics committee country [1]

New Zealand

Date submitted for ethics approval [1]

26/03/2018

Approval date [1]

14/05/2018

Ethics approval number [1]

18/STH/71

Summary

Brief summary

This study is a medical device study on the effect of warm humidified carbon dioxide on optical clarity in laparoscopic cholecystectomy surgery. The medical device being used is called HumiGard and is approved for use in humans and is in routine medical use in several countries. It is manufactured by Fisher and Paykel Healthcare Ltd. Fisher and Paykel Healthcare (referred to as ‘FPH’) is a New Zealand owned medical device company and is the sponsor of this trial. 

Loss of optical clarity during laparoscopic surgery remains a major concern for surgeons. Clear vision in surgery is important not only for safety by preventing accidental injury, but also to improve precision and reduce operative time. The condensation that leads to “fogging” occurs when the temperature of the camera lens is at or below the temperature of the air surrounding the object and this study aims at investigating whether a new surgical humidifier can reduce lens fogging by warming and humidifying the carbon dioxide gas used during laparoscopic cholecystectomies. 

Participants undergoing laparoscopic cholecystectomy surgery at Auckland Hospital or Greenlane Hospital who meet the inclusion and exclusion criteria will be offered the opportunity to participate in the pilot study.

To measure the number of fogging events that occur during a routine procedure, the video feed of the laparoscopic camera will be recorded and analysed post-operatively. This camera and its recordings are nearly entirely internal and so there will be no way to identity participants from the video. In addition to the laparoscopic camera, a camera will be placed directly about the external surgical area as to capture all events that occur outside of the abdomen (not recorded by the laparoscopic camera). 

During surgery, investigators or a research nurse will also take record of other measurements that will be monitored as part of standard of care. The measurements will include data such as core body temperature and the length of the procedure. 

Video/image analysis of laparoscopic camera will be done at a later time point by medical professionals.

Trial website

Trial related presentations / publications

Public notes

Contacts

Principal investigator

Name

Prof John Windsor

Address

Building 599, level 12
ACH Support Building
Park Road
Grafton
Auckland 1142

Country

New Zealand

Phone

+64 9 373 7599

Fax

j.windsor@auckland.ac.nz

Contact person for public queries

Name

Sheryl Fenwick

Address

Building 599, level 12
ACH Support Building
Park Road
Grafton
Auckland 1142

Country

New Zealand

Phone

+64 9 923 1908

Fax

s.fenwick@auckland.ac.nz

Contact person for scientific queries

Name

Lotte van den Heuij

Address

Fisher and Paykel Healthcare
15 Maurice Paykel Place
East Tamaki
Auckland
2013

Country

New Zealand

Phone

+64 9 574 0123

Fax

lotte.vandenHeuij@fphcare.co.nz

Data sharing statement

Will individual participant data (IPD) for this trial be available (including data dictionaries)?

No/undecided IPD sharing reason/comment

What supporting documents are/will be available?

Doc. No.	Type	Citation	Link	Email	Other Details	Attachment
3512	Clinical study report				This will be decided upon completion of the study.

Results publications and other study-related documents

Documents added manually

No documents have been uploaded by study researchers.

Documents added automatically

No additional documents have been identified.

Trial Review

Registering a new trial?

Documents added manually

Documents added automatically